Correction and Update: The State Cannabis Reference Lab Is Not New

CORRECTION AND UPDATE: Connecticut’s Cannabis Reference Lab Is Not New, Home Growers Can Already Access Testing, and State Records Raise New Questions About What CAES Has Been Doing for Years

Connecticut CannaTimes - September 27, 2026

Editor’s Note / Correction: Connecticut CannaTimes published an article on September 23 detailing Connecticut’s little-publicized state cannabis testing program at the Connecticut Agricultural Experiment Station, or CAES, and the state’s expansion into microbiological reference testing.

Since publication, additional records, court filings, state reports and new reporting by CT Insider’s Jordan Nathaniel Fenster have filled in important pieces of the story. They have also made parts of the picture considerably more complicated.

This article corrects and expands our original reporting.

The biggest clarification is simple:

Connecticut is not just now creating a state cannabis laboratory.

CAES has been testing cannabis for the Department of Consumer Protection for years. State records show the program was being developed during the 2021-2022 reporting period, and CAES Director Jason White told CT Insider the formal program began July 1, 2022.

A 2022 CAES presentation was even more explicit. It described the Analytical Chemistry Department as Connecticut’s future “state regulatory testing laboratory” and an:

“Oversight laboratory for private labs”

that would assist DCP with:

“surveillance, investigations, audits, consumer/grower complaints.”

What is new is the expansion of that existing state operation, particularly into microbiological reference testing at CAES’s Griswold Research Center.

And we now know considerably more about how the state intends to use it.

CT Insider added an important piece: the DCP-CAES agreement

On September 26, CT Insider reporter Jordan Nathaniel Fenster published additional reporting on the reference laboratory, including details from a 2025 memorandum of understanding between DCP and CAES.

That reporting adds important information to the public record and to our September 23 article.

According to CT Insider, the agreement calls for CAES to test cannabis, hemp and related products in support of DCP inspection, investigation and enforcement work.

The agencies are also supposed to develop methods for evaluating DCP-licensed private cannabis laboratories. That may include biannual audits.

CAES Director Jason White told CT Insider that CAES work can include:

“verifying private laboratory testing,” audits and complaint samples.

But there is an important limitation.

White also said CAES analyzes samples collected and delivered by DCP inspectors.

That means CAES may provide an independent scientific analysis, but DCP apparently controls what samples are selected and delivered for testing.

That distinction matters.

The reference laboratory does not simply roam the legal cannabis market independently checking whatever it wants. The effectiveness of the system also depends on how DCP selects samples, how frequently laboratories are checked, whether comparison testing is blinded, what constitutes a significant discrepancy and what happens after CAES and a private laboratory disagree.

Many of those details remain unclear publicly.

The new laboratory is an expansion, not the beginning

The MOU provides considerably more detail about the current expansion.

CT Insider reported a $450,000 transfer for the Griswold laboratory buildout and equipment, with an itemized estimate totaling $423,700.

The agreement also provides up to $50,000 annually beginning July 1, 2026 for maintenance, supplies and accreditation.

DCP will fund salaries and benefits for two new CAES positions, an assistant scientist and research technician.

The new microbiological operation is expected to test for total yeast and mold, aerobic microbes, coliforms and pathogens including E. coli, Salmonella, Listeria and four Aspergillus species.

CAES itself now describes its Analytical Chemistry Department as:

“the state reference lab for chemical, and more recently the microbiological testing for the state adult use cannabis program.”

Official CAES page:

https://portal.ct.gov/CAES/ABOUT-CAES/Departments/Analytical-Chemistry

This is therefore better understood as an expansion of an existing government cannabis testing operation into additional microbiological capabilities.

Another correction: the state’s published sample counts do not cleanly reconcile

Our original article relied heavily on a December 2025 CAES Director’s Report stating that CAES had tested more than 265 cannabis samples since the program began.

That statement remains in the official state report.

But after reviewing CAES’s individual annual reports, Connecticut CannaTimes found a problem.

The published annual figures include:

FY 2021-22: 16 marijuana product samples submitted by DCP

FY 2022-23: 117 marijuana product samples submitted by DCP

FY 2023-24: 64 marijuana product samples analyzed and reported to DCP

FY 2024-25: 110 marijuana samples, comprising 327 sub-samples, analyzed and reported to DCP

Those four annual figures total 307, not 265.

That does not necessarily mean either number is wrong.

The reports use different terms including “submitted,” “analyzed” and “tested.” There may be differences involving fiscal years, sample definitions, repeat testing, exclusions or other accounting.

But the numbers do not reconcile on their face.

For that reason, Connecticut CannaTimes is correcting the shorthand characterization of this as simply a “265-sample” program.

The defensible conclusion is that Connecticut has tested hundreds of cannabis samples through CAES, while the exact number and composition of those samples still require reconciliation.

CAES December 2025 Director’s Report:

https://portal.ct.gov/-/media/caes/publications/caes-directors-report-for-website-251210.pdf

Those hundreds of samples should not be called hundreds of private-lab audits

This is another important clarification.

The existence of hundreds of CAES cannabis tests does not establish that Connecticut independently checked hundreds of commercial laboratory results.

The available evidence suggests the CAES workload contains different types of testing.

One category is illicit-market enforcement.

Another may involve licensed products, complaints, label verification, suspect products or other regulatory investigations.

A third category is the one most important to the current “reference laboratory” discussion: independent verification or oversight of Connecticut’s licensed private laboratories.

The public record confirms CAES was intended to perform that oversight function.

What remains unclear is how much of its historical workload was actually devoted to doing it.

We now know CAES results have been used in enforcement

This is no longer hypothetical.

Court records establish that Connecticut has used CAES cannabis testing as evidence in enforcement matters.

High Bazaar

The Attorney General’s High Bazaar court filing provides a particularly clear example.

According to the filing, an investigator purchased cannabis at High Bazaar on November 8, 2023.

On November 20, 2023, the investigator transmitted an eighth of an ounce of that cannabis to CAES for THC analysis.

CAES completed its analysis January 3, 2024.

The state alleged the product exceeded 3 percent total THC on a dry-weight basis, establishing that the material qualified as cannabis under Connecticut law.

The sequence is important:

Investigator purchase → government custody → CAES testing → laboratory result → enforcement evidence.

Attorney General High Bazaar court filing:

https://portal.ct.gov/-/media/ag/press_releases/2024/high-bazaar—e-filed-docs-combined.pdf

Smoker’s Corner

High Bazaar is not the only enforcement matter identified during our records review.

Separate court materials reviewed by Connecticut CannaTimes involving Smoker’s Corner in Norwich identify another cannabis testing episode involving a product described as Frosty M.A.C. Flower, with a reported result of approximately 14.6 percent total delta-9 THC associated with the state testing record.

The Smoker’s Corner litigation arose from undercover purchases at the Norwich business in 2023. Public court records describe investigators purchasing cannabis from the business, which did not hold a Connecticut cannabis establishment license.

This matters because it provides another window into what some of the otherwise unexplained CAES cannabis workload actually represented.

Not every state test was necessarily checking whether Northeast Laboratories, AltaSci or Analytics Labs got a commercial test correct.

At least part of the state laboratory’s historical workload was being used for direct cannabis enforcement.

That makes the missing sample-level accounting even more important.

Other smoke-shop enforcement could account for additional samples, but that is not yet proven

Connecticut conducted numerous enforcement actions involving unlicensed cannabis retailers and wholesalers during this same period.

They include cases involving Greenleaf Farms, Anesthesia Convenience & Smoke, Planet Zaza, RZ Smoke, Star Enterprise, Shark Wholesale and later enforcement against additional smoke shops and convenience stores.

Some state releases even include quantitative claims about THC concentrations.

But Connecticut CannaTimes has not yet established that CAES generated every one of those results.

The numbers could have come from CAES, another laboratory, product labeling or other evidence.

Those cases should therefore be treated as leads, not automatically added to the CAES testing count.

That distinction is important because it illustrates the larger problem.

We know hundreds of samples were submitted or tested.

We know at least some were enforcement samples.

We know CAES was also intended to oversee private laboratories.

What we still do not have publicly is a clean ledger explaining what each sample was, why it was tested and what happened afterward.

The question is no longer whether CAES can check private labs

Connecticut’s own records answer that question.

It can.

The 2022 CAES presentation specifically called the state operation an:

“Oversight laboratory for private labs.”

The new MOU reportedly includes methods for evaluating licensed laboratories and potentially biannual audits.

White has now publicly said the work can include verifying private laboratory testing.

So the more important questions are retrospective:

How many private-lab results has CAES actually checked since the program began?

Which laboratories were checked?

Were the tests blind?

How often did CAES and the commercial laboratory agree?

How often did they disagree?

How large were the discrepancies?

Did disagreements lead to investigations, retesting, recalls, warnings or disciplinary action?

Those questions cannot be answered from aggregate annual reports.

The state’s own description creates another question

CAES says its cannabis program has tested products for cannabinoids as well as pesticides, mycotoxins, terpenes and heavy metals.

The products tested over the years reportedly include flower, gummies, oils, chocolates, tablets, concentrates, vape products, seltzers, live resin and unusual products including THC-lined straws and pizza dough.

Reported THC concentrations ranged from 0.02 percent to 94.6 percent.

That is a remarkably broad universe of products.

Yet the public generally cannot look up those CAES results product by product.

The state publishes extensive information about Connecticut cannabis products and private laboratory Certificates of Analysis.

What remains difficult to examine is the state’s own independent testing record.

There is also a major difference between a COA and a laboratory audit

Our investigation since the original article has also made another distinction increasingly important.

A public Certificate of Analysis is not necessarily the complete laboratory record.

The underlying laboratory record can include instrument data, test runs, sample identifiers, amendments, version history and information that may not be obvious from the final public-facing certificate.

That means meaningful verification of a laboratory is considerably more complicated than comparing two PDFs.

A serious audit may require examination of sampling, chain of custody, methods, standard operating procedures, instrumentation, underlying test records, employee practices and quality-control systems.

The new reference-lab structure may provide Connecticut with tools to do exactly that.

The remaining question is how those tools are being used.

Meanwhile, home growers can already get their cannabis tested in Connecticut

This is another important clarification, particularly after recent social-media discussion about the new state reference laboratory.

Connecticut law already contemplated testing access for ordinary consumers.

Current Connecticut law directs DCP to establish procedures through which cannabis testing laboratories accept marijuana samples from caregivers, qualifying patients and consumers.

See CGS §21a-408r:

https://www.cga.ct.gov/current/pub/chap_420f.htm

But there is an even more practical development that many Connecticut home growers apparently do not know about.

Northeast Laboratories in Rocky Hill is currently advertising cannabis testing directly to Connecticut home growers.

Its cannabis FAQ states:

“Yes, we can test your cannabis!”

The laboratory says its services are available to licensed growers and home growers in Connecticut and include potency, terpenes, pesticides, heavy metals, microbial contaminants and other testing.

For home growers, Northeast says it recommends potency and contaminant testing for personal-use cannabis.

It also says individual tests are available when a full compliance panel is unnecessary.

And the submission instructions are explicit:

“For home growers interested in testing their product, samples may be submitted in person at our Rocky Hill facility.”

Northeast also says:

“Walk-ins for homegrown sample submission are welcome!”

Northeast Cannabis FAQ:

https://www.nelabsct.com/faq/cannabis/

Northeast Cannabis Testing Services:

https://www.nelabsct.com/testing-services/cannabis/

This deserves attention because public discussion of the new CAES reference laboratory can create the impression that Connecticut home growers currently have nowhere to independently test their cannabis.

At least at Northeast Laboratories, that is not true.

A Connecticut home grower can currently bring a homegrown cannabis sample to the Rocky Hill laboratory for testing.

That service is separate from CAES.

CAES is the government reference and enforcement laboratory. Northeast is a licensed private cannabis testing laboratory that is currently advertising testing services directly to Connecticut home growers.

Those are two very different functions.

The timing of the microbiology expansion also deserves scrutiny

The CAES expansion is occurring while Connecticut’s cannabis testing laws and regulatory structure are changing.

Public Act 26-8 changes portions of Connecticut’s statutory cannabis-testing architecture effective October 1, 2026.

The existing statutory framework contains detailed requirements concerning microbial contaminants, Aspergillus and approved molecular testing methods including qPCR.

PA 26-8 moves significant testing detail toward standards established through DCP’s regulatory framework.

Public Act 26-8:

https://www.cga.ct.gov/2026/act/pa/pdf/2026PA-00008-R00HB-05350-PA.pdf

That would be relatively straightforward if Connecticut had a settled permanent adult-use regulatory framework.

It does not.

DCP’s broad adult-use rulemaking effort, PR2024-053, did not ultimately become the permanent regulatory framework. DCP continues operating the adult-use program through Policies and Procedures that have force of law, and legislation has extended that temporary structure.

At essentially the same time, DCP is funding expanded state microbiological reference testing.

That does not prove the two developments are causally related.

But it makes transparency about the reference laboratory’s role increasingly important.

What the CT Insider article clarifies, and what remains muddy

Fenster’s reporting substantially advanced this story.

It established more detail about the 2025 MOU, funding, staffing, DCP sample collection, potential laboratory audits and CAES’s role in verifying private testing.

But the new information also demonstrates why the story is more complicated than simply:

“Connecticut is getting a new cannabis reference lab.”

The state already had a cannabis testing program.

The state had already described CAES as an oversight laboratory for private labs.

DCP had already been submitting cannabis for years.

CAES testing had already entered enforcement cases.

Hundreds of samples had already passed through the program.

The new Griswold microbiology laboratory is an expansion of an existing state cannabis testing program, not the beginning of one.